Activation of the protein kinase Akt in peripheral blood mononuclear cells. Association with insulin and insulin-like growth factor levels in the blood of patients with cancer and diabetes
Vol. 24 No. 3 (2019), ORIGINAL PAPERS
Vol. 24 No. 3 (2019)

Activation of the protein kinase Akt in peripheral blood mononuclear cells. Association with insulin and insulin-like growth factor levels in the blood of patients with cancer and diabetes

ORIGINAL PAPERS
https://doi.org/10.31793/1680-1466.2019.24-3.228
Published September 20, 2019
T.S. Vatseba
SHEI «Ivano-Frankivsk National Medical University», Ivano-Frankivsk
L.K. Sokolova
SI «V.P. Komisarenko Institute of endocrinology and metabolism of NAMS of Ukraine», Kyiv
V.V. Pushkarev
SI «V.P. Komisarenko Institute of endocrinology and metabolism of NAMS of Ukraine», Kyiv
O.I. Kovzun
SI «V.P. Komisarenko Institute of endocrinology and metabolism of NAMS of Ukraine», Kyiv
B.B. Guda
SI «V.P. Komisarenko Institute of endocrinology and metabolism of NAMS of Ukraine», Kyiv
V.M. Pushkarev
SI «V.P. Komisarenko Institute of endocrinology and metabolism of NAMS of Ukraine», Kyiv
M.D. Tronko
SI «V.P. Komisarenko Institute of endocrinology and metabolism of NAMS of Ukraine», Kyiv
pdf (Українська)

Keywords

Akt, insulin, insulin-like growth factor 1, peripheral blood mononuclear cells, cancer, diabetes.

How to Cite

Vatseba, T., Sokolova, L., Pushkarev, V., Kovzun, O., Guda, B., Pushkarev, V., & Tronko, M. (2019). Activation of the protein kinase Akt in peripheral blood mononuclear cells. Association with insulin and insulin-like growth factor levels in the blood of patients with cancer and diabetes. Endokrynologia, 24(3), 228-232. https://doi.org/10.31793/1680-1466.2019.24-3.228
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX
Crossref
Scopus
Google Scholar
Europe PMC

Abstract

Signal cascade PI3K/Akt/mTOR/p70S6K plays an important role in the pathogenesis of cancer and diabetes. Macrophages and lymphocytes are involved in the development of diabetes, diabetic atherosclerosis, the formation of tissue resistance to insulin, as well as in the immune response to cancer and tumor support. The aim of the study was to determine the activation of Akt by mTORC2 kinase in peripheral blood mononuclear cells (PBMC) of patients with type 2 diabetes and cancer. Material and methods. The following groups were studied: 1 — the control group, 2 — patients with breast cancer, 3 — patients with endometrial cancer, 4 — patients with bowel cancer, 5 — patients with pancreatic cancer. The amount of phospho-Akt (p-S473), insulin and insulin-like growth factor‑1 (IGF‑1) was determined using enzyme immunoassay. Results. Insulin and IGF‑1 levels are higher in the blood of patients with breast and endometrial cancer compared with control, as well as bowel and pancreatic cancer. The change in the content of activated Akt in PMBC generally corresponds to the concentration of insulin and IGF‑1 in the blood. The differences between breast/endometrial cancers and pancreatic/bowel cancers with IGF‑1/insulin content in the blood and Akt activation in PMBC can be explained by the presence of hormonal background (estrogens) specific for the first two types of cancer. Conclusion. Chronic diseases such as type 2 diabetes and cancer can affect the signaling mechanisms in blood cells. The state of Akt phosphorylation in PMBC may indicate the activity of mTORC1 and its substrates, which may be important for the assessment of the pathological process and the effectiveness of treatment.

https://doi.org/10.31793/1680-1466.2019.24-3.228
pdf (Українська)

References

1. Manning BD, Toker A. AKT/PKB Signaling: navigating the network. Cell. 2017 Apr;169:381-405.
2. De Marco P, Cirillo F, Vivacqua A, Malaguarnera R, Belfiore A, Maggiolini M. Novel aspects concerning the functional cross-talk between the insulin/IGF-I system and estrogen signaling in cancer cells. Front Endocrinol (Lausanne). 2015 Mar;6:30.
3. Senovillan L, Vacchellin E, Galon J, Adjemian S, Eggermont A, Fridman WH, et al. Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology. 2012 Nov;1(8):1323-43.
4. de Oliveira CE, Oda JM, Losi Guembarovski R, de Oliveira KB, Ariza CB, Neto JS, et al. CC chemokine receptor 5: the interface of host immunity and cancer. Dis Markers. 2014;2014:126954.
5. Тронько НД, Пушкарев ВМ, Соколова ЛК, Пушкарев ВВ, Ковзун Е.И. Молекулярные механизмы патогенеза сахарного диабета и его осложнений. Киев: Медкн., 2018. 261 с. (Tronko ND, Pushkarev VM, Sokolova LK, Pushkarev VV, Kovzun OI. Molecular mechanisms of pathogenesis of diabetes and its complications.
K.: Publishing house Medkniga, 2018. 264 p. (In Russian).
6. Dituri F, Mazzocca A, Giannelli G, Antonaci S. PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors. Clin Dev Immunol. 2011;2011:947858.
7. Kim LC, Cook RS, Chen J. mTORC1 and mTORC2 in cancer and the tumor microenvironment. Oncogene. 2017 Apr;36(16): 2191-201.
8. Copps KD, HançerNJ, Qiu W, White MF. Serine 302 phosphorylation of mouse insulin receptor substrate 1 (IRS1) is dispensable for normal insulin signaling and feedback regulation by hepatic S6 kinase. J Biol Chem. 2016 Apr;291(16):8602-17.
9. Copps KD, White MF. Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1and IRS2. Diabetologia. 2012 Oct;55(10):2565-2582.
10. Rad E, Murray JT, Tee AR. Oncogenic signalling through mechanistictarget of rapamycin(mTOR): a driver of metabolic transformation and cancer progression. Cancers (Basel). 2018 Jan;10(1): E5.
11. Jhanwar-Uniyal M, Amin AG, Cooper JB, Das K, Schmidt MH, Murali R. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects. Adv Biol Regul. 2017 May;64:39-48.
12. Brick DJ, Gerweck AV, Meenaghan E, Lawson EA, Misra M, Fazeli P, et al. Determinants of IGF1 and GH across the weight spectrum: from anorexia nervosa to obesity. Eur J Endocrinol. 2010 Aug;163:185-91.
13. Klement RJ, Fink MK. Dietary and pharmacological modification of theinsulin/IGF‑1system: exploiting the full repertoire against cancer. Oncogenesis. 2016 Feb;5: e193.
14. Fine EJ, Feinman RD. Insulin, carbohydrate restriction, metabolic syndromeand cancer. Exp Rev Endocrin Metab. 2015 Jan;10(1): 15-24.
15. Yu H, Shu XO, Li BD, Dai Q, Gao YT, Jin F, et al. Joint effect of insulin-like growth factors and sex steroids on breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2003 Oct;12(10):1067-73.

Downloads

Download data is not yet available.